# PortfolioAI — Gate K-FINAL: Portfolio Sector-Coverage Closure

**Contract:** `GATE_K_FINAL_PORTFOLIO_COVERAGE_V1`  
**Date:** 22 September 2026  
**Branch:** `r4n-pharma-subprofile-architecture`  
**PR:** #101 OPEN / DRAFT / UNMERGED  
**Status:** LOCAL VALIDATION PENDING

## 1. Purpose

K-FINAL is the formal closure stage for Gate K. It does not introduce a new sector methodology, threshold policy, provider action, persistence path, deployment, or trading capability.

Its job is to prove that the current portfolio has a complete and fail-closed sector-driven research architecture.

## 2. Portfolio-wide closure matrix

Runtime artifact:

`src/features/research/kFinalPortfolioCoverage.ts`

The matrix is generated from the frozen 238-equity K1/K5 portfolio routing snapshot.

Each holding receives exactly one architecture state:

- `ARCHITECTURE_READY`
- `METHODOLOGY_NOT_AVAILABLE`
- `REVIEW_REQUIRED`
- `NOT_APPLICABLE`

For `ARCHITECTURE_READY` holdings:
- engine/profile routing is complete;
- score state is `EVIDENCE_DEPENDENT`;
- recommendation state is `POLICY_AND_EVIDENCE_DEPENDENT`.

This intentionally does not claim that every current holding already has complete evidence, a computable score, or an executable recommendation.

For unsupported methodology:
- score → `SCORE_NOT_COMPUTABLE`;
- recommendation → `RECOMMENDATION_NOT_COMPUTABLE`.

For unresolved/conflicting classification:
- method/score/recommendation → `REVIEW_REQUIRED`.

## 3. Final acceptance coverage

K-FINAL validates the canonical 18 acceptance conditions through a consolidated regression:

1. every frozen current holding has an explicit research-engine architecture state;
2. cross-sector authority isolation remains complete;
3. supported future stocks remain portable without ticker-specific methodology;
4. one universal Research workspace remains authoritative;
5. missing mandatory evidence remains fail-closed;
6. explicit N/A remains distinct from missing;
7. recommendation safety semantics remain intact;
8. complete registry-driven pairwise isolation remains intact;
9. TORNTPHARM/AUROPHARMA golden controls remain stable;
10. unsupported sectors report `METHODOLOGY_NOT_AVAILABLE`;
11. score persistence remains OFF;
12. recommendation persistence remains OFF;
13. position sizing remains OFF;
14. Gate K does not authorize AI interpretation activation;
15. production mutation/migration remains OFF;
16. deployment remains OFF;
17. PR merge remains OFF;
18. automatic trading remains OFF.

## 4. Important interpretation

Gate K portfolio coverage means:

```text
classification + methodology architecture = complete/fail-closed
```

It does **not** mean:

```text
all 238 holdings already have full evidence + scores + recommendations
```

Legitimate evidence insufficiency remains a correct `SCORE_NOT_COMPUTABLE` / `INSUFFICIENT` outcome.

## 5. Safety

No action in K-FINAL authorizes:
- production Supabase mutation or migration;
- provider refresh;
- score persistence;
- recommendation persistence;
- position sizing;
- AI interpretation activation;
- portfolio mutation;
- scheduler changes;
- deployment;
- PR merge;
- automatic trading.

## 6. Consolidated validation

Run locally:

```bash
git pull
bash scripts/k-final-validate-portfolio-coverage.sh
```

This runs the K-FINAL closure test plus K5 isolation/routing/portability, K3 N/A semantics, K2 recommendation safety, Pharma read-only downstream-safety controls, universal workspace regression, and TypeScript.

The suite is lifecycle-stable: it does not assert stale pre-approval or pre-promotion states.

## 7. Exit

If the consolidated command passes:

```text
Gate K-FINAL = COMPLETE / PASS / CLOSED
Gate K = COMPLETE / PASS
Sector-specific research layer = PORTFOLIO COVERAGE COMPLETE
```

PR #101 remains OPEN / DRAFT / UNMERGED until a separate explicit merge decision.
